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Abstract 
Type 2 diabetes mellitus is a major risk factor for cardiovascular disease. The likelihood of 
mortality significantly increases when type 2 diabetes mellitus and cardiovascular disease 
coincide (Zinman et al., 2015). Consequently, cardiovascular disease is the leading cause of 
morbidity and mortality in patients with type 2 diabetes mellitus.  Reducing cardiovascular risk 
is essential in successful management of diabetes. In 2015, the EMPA-REG OUTCOME trial 
demonstrated that the SLGT2 inhibitor, empagliflozin, provided significant cardiovascular 
benefits, among other protective effects, beyond simply lowering blood glucose levels (Naing, 
Poliyedath, Khandelwal & Sigala, 2016). This independent study aims to address the effects 
empagliflozin has on improving cardiovascular mortality and morbidity in type 2 diabetes 
mellitus patients.  
Keywords:  type 2 diabetes mellitus, empagliflozin, cardiovascular disease 
 
USE OF EMPAGLIFLIZON TO REDUCE CV RISK IN T2DM 4 
Background  
 Type 2 diabetes mellitus is a chronic disease that requires long term medical treatment 
and monitoring to effectively limit the devastating progression of the disease process. The effects 
type 2 diabetes mellitus has on the cardiovascular system have been extensively researched, 
proving patients are at an increased risk for myocardial infarction, stroke, and heart failure. 
Cardiovascular disease accounts for an overwhelming percentage of mortality in patients with 
type 2 diabetes mellitus. Approximately two thirds of people with diabetes die of heart disease or 
stroke (Khardori, 2017).  
Treatment goals for type 2 diabetes mellitus consists of lifestyle modifications including 
diet, exercise, smoking cessation, and pharmacotherapy (Dixit, Yoon, Volino, & Mansukhani, 
2015).  Although, there are many anti-hyperglycemic agents available, the following paper will 
specifically focus on the sodium glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin 
(Jardiance®).  
SGLT2 inhibitors improve glycemic control by inhibiting reabsorption of glucose from 
the proximal tubules in the kidney, lowering the renal threshold for glucose, thus increasing 
urinary glucose excretion (Scott, 2014; Dixit et al., 2015; McGovern, Feher, Munro, & Lusignan, 
2017). Since the mechanism of action of empagliflozin is not insulin-dependent, it may be used 
in patients with nonfunctional or impaired pancreatic beta cells and in combination with other 
antidiabetic agents given its low risk of hypoglycemic effects (Dixit et al., 2015).  
In December 2016, the US Food and Drug Administration (FDA) approved empagliflozin 
(Jardiance ®) for the “new indication of improving survival in adults with type 2 diabetes and 
cardiovascular disease” (Tucker, 2016, para 1). The Empagliflozin Cardiovascular Outcomes and 
Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial was the first clinical trial to 
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demonstrate a significant reduction in cardiovascular effects with the use of an antidiabetic agent 
(McGovern et al., 2017; Simo & Hernandez, 2016).  
This independent study aims to address the effects empagliflozin has on improving 
cardiovascular mortality and morbidity in type 2 diabetes mellitus patients. The foundation of 
this report is based on the case of a 60 year-old Caucasian female with a ten-year history of type 
2 diabetes mellitus with a significant family history of cardiovascular disease.  
Case Report  
History  
A 60-year-old Caucasian female presented to her primary care office for a diabetes 
follow-up. She was diagnosed with type II diabetes mellitus 10 years ago. Since diagnosis, she 
has maintained disease progression on 500 mg Metformin twice daily, along with lifestyle 
modifications, including diet and exercise. She was last seen in the clinic six months ago. Her 
hemoglobin A1C was 8.2% at that time. She was instructed to meet with a diabetes educator to 
aid in making healthy food choices and follow-up in six months. Today, she states she feels well 
and denies complaints. She monitors her blood glucose levels twice weekly, with results ranging 
from 150-200 mg/dL. She denies any hypoglycemic episodes. She reports strict compliance with 
her medications and denies medication side effects. Her typical diet includes: cereal for 
breakfast, fried chicken and French fries for lunch, a hamburger for supper, and numerous sweet 
treats for snacks throughout the day. She walks about two miles every day for exercise. She 
denies use of tobacco, illicit drugs, or alcohol. Her last eye exam was 3 months ago and she 
states she follows up on this annually.  
Her past medical history includes hypertension (age of onset 42) and hyperlipidemia (age 
of onset 45). She has a significant family history including; heart disease in both of her parents. 
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Her mother died at the age of 80 from what she describes as a “silent” heart attack. Her father 
also passed away at age 89 from cardiac complications, specifics unknown.   
Along with her diabetic medication, she is also taking 81 mg Aspirin daily, 20 mg 
Lisinopril daily, 20 mg Atorvastatin daily, and a multivitamin. She reports an allergy to 
penicillin.  
Review of Systems and Physical Exam 
 The review of systems was grossly negative. She denies polyuria, polyphagia, polydipsia, 
weight loss or gain, fever, chills, sleep disturbance, nausea, diarrhea, constipation, headaches, 
numbness/tingling to bilateral extremities, weakness, dizziness, chest pain, or dyspnea. She does 
report ongoing fatigue for the last few months, however, this has not interfered with her activities 
of daily living.  
 Her vitals were as follows: blood pressure 148/98, heart rate 80, respirations 20, and 
temperature 98.6, BMI 27. Her physical exam was unremarkable. She was alert and oriented, 
well-groomed, well-nourished and in no acute distress.  Lung fields were clear upon auscultation 
with a normal respiratory rate and rhythm. S1 and S2 were also auscultated without adventitious 
heart sounds, including murmurs, gallops or clicks. Her abdomen was soft, nontender, 
nondistended, with active bowel sounds in all four quadrants. No edema was present. Her 
diabetic foot exam revealed warm, dry, intact skin to bilateral feet, pulses were 2+ bilaterally, 
monofilament exam was 5/5 bilaterally, and no sores or calluses were noted. 
 Lab workup included a TSH for ongoing fatigue (results were within normal limits), a 
lipid panel, BMP, CBC, and Hemoglobin A1C. Her fasting lipid panel revealed elevated 
cholesterol at 209, triglycerides 184, HDL 31, and LDL 95. Her glucose was 96. BUN 9, serum 
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creatinine 0.8. Her CBC was grossly normal. The hemoglobin A1C increased from 8.2% 6 
months ago, to 8.5% today.  
Management of Care 
 In discussion with the patient, we opted to initiate a SGLT2 inhibitor, Jardiance 10 mg 
every morning, in addition to her metformin twice daily. She should continue to monitor her 
blood glucose levels two to three times a week and record those levels. Lifestyle modification 
was reinforced, including consuming a healthier, well-balanced, diabetic meal, and increasing 
her physical activity daily. Given her elevated blood pressure today, she was instructed to 
monitor her blood pressures at home daily for one week and call the clinic with those results. Her 
atorvastatin was increased to 40 mg daily to reduce her lipid levels, thus reducing risk for heart 
attacks and stroke. She was instructed to follow-up in the clinic in 3 months, including a recheck 
of her Hgb A1C, fasting lipid panel, and glucose levels.  
Literature Review 
The above case report represents a female patient at risk for developing cardiovascular 
disease. Although, she does not have a personal medical history of cardiac disease, her 
significant family history and a number of other risk factors increase her risk for developing 
cardiovascular disease, including hypertension, hyperlipidemia, and a BMI indicating she is 
overweight. Along with diet and exercise, pharmalogical interventions can help reduce the risk of 
increased cardiovascular disease. In 2015, the EMPA-REG OUTCOME trial was published 
identifying intriguing data supporting the use of the SGLT2 inhibitor, empagliflozin, in 
significantly reducing rates of death from cardiovascular causes in type 2 diabetes mellitus 
patients (Zinman et al., 2015).  A literature review was conducted on the current evidence SGLT2 
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inhibitor, empagliflozin, has on reducing cardiovascular outcomes and mortality in type 2 
diabetes mellitus patients.  
Findings 
 The EMPA-REG OUTCOME trial is currently the first and only published trial 
specifically assessing the cardiovascular safety profile in SGLT2 inhibitors.  The trial was a non-
inferiority, randomized, double-blind, placebo-controlled trial evaluating the cardiovascular 
effects once-daily empagliflozin (dosed at 10 mg or 25 mg) vs. placebo had on adults with type 2 
diabetes at a high cardiovascular risk who were receiving standard care (Zinman et al., 2015). 
The primary outcome focused on death from cardiovascular causes, nonfatal myocardial 
infarction, and nonfatal stroke.  7020 study patients were observed in this trial, of whom were 
adults with type 2 diabetes mellitus, had a body-mass index less than 45, had a GFR of at least 
30, had established cardiovascular disease, and had a Hemoglobin A1C between 7.0% and 10.0% 
(Zinman et al., 2015).  It is important to note patients in this trial had established cardiovascular 
disease and cardiovascular risk factors, including hypertension and dyslipidemia, and were 
treated according to guidelines and standard care with the use of renin–angiotensin–aldosterone 
system inhibitors, statins, and aspirin (Zinman et al., 2015).  
Early in the trial the results indicated those receiving empagliflozin with type 2 diabetes 
mellitus and at high risk for cardiovascular events, had a lower rate of mortality from 
cardiovascular related causes (Zinman et al., 2015).  A 38% relative risk reduction in 
cardiovascular mortality and a 32% risk reduction in all-cause mortality among patients with 
type 2 diabetes mellitus and cardiovascular disease was observed in patients taking empagliflozin 
vs. placebo (Tucker, 2016; Simo & Hernandez, 2016; Martens, Mathieu, & Verbrugge, 2017; 
Secrest, Udell, & Filion, 2017). Although, there is limited data available to understand and 
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support exactly why empagliflozin demonstrated such a substantial cardiovascular benefit shortly 
after randomization, many experts have speculated on different hypotheses. McGovern et al. 
(2017) have commented that the cardiovascular benefits may have been achieved due to the 
diuretic effect SGLT2 inhibitors have, or rather suggesting SLGT2 inhibitors act on reducing 
cardiac preload and afterload, or simply more efficient use of ketone bodies relieves some of the 
strain on the myocardial tissue. Regardless, additional studies and research are needed to fully 
understand and support these hypotheses. Furthermore, the EMPA-REG OUTCOME trial did not 
show any significant differences in the rates of myocardial infarction or stroke (Zinman et al., 
2015; Simo & Hernandez, 2016; Martens et al., 2017).  
Zinman et al. (2015) suggests “the mechanisms behind the cardiovascular benefits of 
empagliflozin are multidimensional” (p. 2126) including, weight reduction by approximately 2-4 
kg, reduction in systolic blood pressure by about 4-6 mm HG, an increase in plasma volume by 
about 0.8 g/dL of hemoglobin, and about a 1% reduction in hemoglobin A1C levels (Secrest et 
al., 2017; Martens et al., 2017).  
Studies have also revealed significant reductions in heart failure admissions (decreased 
by about 33%) and end-stage kidney disease (Martens et al., 2017).  With the use empagliflozin, 
results have suggested a reduction in vascular stiffness and improved endothelial function 
leading to an overall reduction in cardiac demand (Zinman et al., 2015). All of the 
abovementioned factors are known to improve cardiovascular risk.  
The EMPA-REG OUTCOME trial has successfully provided data to support the use of 
empagliflozin long term, as well as compelling evidence that empagliflozin reduces 
cardiovascular risk and mortality (Zinman et al., 2015). Throughout the literature, it has been 
identified that empagliflozin is a reasonable choice for add-on therapy in patients with type 2 
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diabetes mellitus and a high cardiovascular risk (Naing et al., 2016; Simo & Hernandez, 2016; 
Secrest et al., 2017).  Current guidelines and recommendations continue to recommend 
metformin as monothereapy until treatment has failed as the primary approach, at which point 
empagliflozin may be started as a second-line treatment (Secrest et al., 2017). Insufficient data is 
available to start any other antidiabetic agents first line or as monotherapy (Secret et al., 2017).  
Adverse effects 
It is noted throughout the literature that empagliflozin is generally well-tolerated. 
However, similar to any medication, it comes with a few notable adverse effects. Most notably, 
there is an increased rate of genital infections reported in those who were treated with 
empagliflozin vs placebo (Secrest et al., 2017). These infections were reported as mild to 
moderate in intensity and most commonly occurred in females (Scott, 2014; Kohler et al., 2016; 
Zimmermann, 2016).  Over a time period of three years, 10% of women and 5% of men reported 
a genital mycotic infection (Zimmermann, 2016). 
 Secondly, a meta-analysis of more than 35,000 patients revealed a 15% relative risk for 
developing a urinary tract infection (Martens et al., 2017). Understandably, patients with a 
previous history of UTIs are more likely to develop these infections while on empagliflozin 
(Dixit et al., 2015).  Complicated urinary tract infections, such as pyelonephritis or urosepsis, 
rates were similar in both placebo (1.8%) and empagliflozin (1.7%) (Naing et al., 2016). 
Thirdly, volume depletion secondary to diuresis may also occur in patients at high risk, 
including the elderly, those using diuretics, or CKD patients (Martens et al., 2017). A meta-
analysis conducted by Dixit et al. (2015) revealed approximately 0.5% of patients treated with 10 
mg empagliflozin experienced adverse effects related to volume depletion, including 
dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope. Similarly, 0.3% 
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of patients treated with placebo and 25 mg empagliflozin experienced the same effects (Dixit et 
al., 2015).  The incidence of volume depletion was similar between empagliflozin and placebo at 
baseline, however the incidence increased in patients who received a loop diuretic at baseline by 
1.5% (Kohler et al., 2016). Therefore, assessment and correction of volume depletion prior to 
initiation of empagliflozin is recommended (Woo, 2015).  
 Lastly, since hypoglycemia is a concerning and potentially detrimental adverse effect, it 
is important to note that empagliflozin was not associated with an increased risk of 
hypoglycemia compared with placebo, unless used in combination with sulfonylurea and/or basal 
insulin, which are previously known to cause hypoglycemic episodes (Kohler et al., 2016).  
Study Limitations/ Future Implications 
 The EMPA-REG OUTCOME trial was revolutionary in publishing data supporting 
empagliflozin and its effects on improving survival in adults with type 2 diabetes mellitus and 
cardiovascular disease. However, there are limitations and a need for future research to be 
completed. 
The EMPA-REG OUTCOME trial only involved participants with high cardiovascular 
risk in their study. There is no clinical evidence or long-term data reporting morbidity and 
mortality in patients with low or no pre-existing cardiovascular disease. It is unknown if the use 
of SLGT2 inhibitors in this patient population would improve their cardiovascular risk profile 
(Secrest et al., 2017; Zimmermann, 2016; McGovern et al., 2017). It is plausible to expect 
similar benefits in the same high risk group, however, we cannot assume the same is true in a 
population with less risk (McGovern et al., 2017). A UK cross-sectional analysis of the EMPA-
REG OUTCOME trial found that only a small proportion of the population had the same high 
cardiovascular risk as those involved in the EMPA-REG OUTCOME trial. Further data is needed 
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to identify possible cardiovascular benefits in those that do not fit this high cardiovascular risk 
profile (McGovern et al., 2017).  
 Furthermore, an article by Tucker (2016) reported that a little under half of the FDA panel 
members were skeptical about so quickly approving this new indication based on the research of 
a single study in a relatively new class of antidiabetic agents. Head-to-head trials of 
empagliflozin and other SGLT2 inhibitors have not yet been completed and published (Dixit et 
al., 2015). Upcoming trials, including the canagliflozin cardiovascular assessment study 
(CANVAS) and the Multicenter Trial to Evaluate the Effect of Dapagliflozin (DECLARE-
TIMI58), will provide evidence of these outcomes and hopefully elude to whether these benefits 
are related to empagliflozin alone or are a class effect (Martens et al., 2017).  
 Future research is also warranted to identify the use of empagliflozin in specific patient 
populations (e.g. children, adolescents, elderly), those with multiple co-morbidities, those with 
CKD (the data published is limited), the use of empagliflozin in combination with other 
antidiabetic agents, aside from metformin, as well as understanding the cardiovascular benefits 
when used as monotherapy (Dixit et al., 2015; Simo & Hernandez, 2016; McGovern et al., 2017; 
Secrest et al., 2017).   
Discussion 
The presented evidence and review of the literature demonstrates empagliflozin is an 
excellent antidiabetic add-on agent in patients who have type 2 diabetes mellitus and have a high 
cardiovascular risk profile.  Numerous systematic reviews and meta-analyses support the 
cardiovascular safety of empagliflozin (Secrest et al., 2017). Although, more research and trials 
broadening the population group are needed to determine if the use of empagliflozin and its 
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associated cardiovascular benefits are similar, the use of empagliflozin to reduce cardiovascular 
mortality in high risk populations is clear.   
Learning Points 
• Continue to  recommend metformin as monothereapy until treatment has failed as 
the primary approach, at which point empagliflozin may be started as a second-
line treatment 
• The literature and evidence supports the use of empagliflozin as add-on agent to 
metformin in patients with high cardiovascular risk to reduce the rate of mortality 
and morbidity 
• Empagliflozin significantly reduced rates of death from cardiovascular disease, 
reduced hospitalizations for heart failure, and reduced death related to any cause 
• For patients with low cardiovascular risk, no clinical evidence currently supports 
the preferential use of SGLT2 inhibitors to improve cardiovascular risk profiles 
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